Nanobiotix reports NBTXR3 NSCLC data and €86m raise

Nanobiotix has published its first-half 2026 operational and financial update, reporting encouraging early data across multiple clinical programmes for JNJ-1900 (NBTXR3), its hafnium oxide nanoparticle radioenhancer, and confirming that a €86 million follow-on equity raise completed in May has extended the company's cash runway to 2029.

The Paris and Cambridge-headquartered company held €110.9 million in cash as of 30 June 2026, up from €52.8 million at year-end 2025 following the oversubscribed global offering. Net loss for the half widened to €34.3 million from €5.4 million in the same period of 2025, though the prior-year comparator was inflated by a €21.2 million non-cash IFRS 15 revenue item recognised when Johnson and Johnson assumed sponsorship of the NANORAY-312 Phase 3 study.

Clinical data across NSCLC and head and neck cancer

The most closely watched dataset came from a Phase 1 study of NBTXR3 in inoperable locoregionally recurrent NSCLC amenable to re-irradiation, sponsored by MD Anderson Cancer Center and presented at the 2026 World Conference on Lung Cancer. At a median follow-up of 12 months across all 24 enrolled patients, the one-year locoregional control rate was 79%, one-year local progression-free survival was 61%, and one-year overall survival was 70%. Crucially, no dose-limiting toxicities and no Grade 3 or higher adverse events related to NBTXR3 or its injection procedure were recorded, and the recommended Phase 2 dose was set at 33% of gross tumour volume. Investigators concluded the agent may permit clinically meaningful local control at substantially lower re-irradiation doses than standard practice.

Separately, Part 1 data from the Johnson and Johnson-led Phase 2 CONVERGE study in Stage 3 unresectable NSCLC were updated at ESTRO 2026. In a cohort of seven patients who had received the full treatment regimen of NBTXR3 followed by concurrent chemoradiotherapy and consolidation durvalumab, the investigator-reported overall response rate reached 85.7% and the complete response rate was 57.1%. The company noted that complete response rates with the current standard of care, concurrent chemoradiation plus durvalumab, run at approximately 15%, citing published data from the PACIFIC trial. Deepening responses over time were observed, which the company positioned as suggestive of long-term durability, though the cohort remains very small.

For the Phase 3 NANORAY-312 study in platinum-ineligible locally advanced head and neck squamous cell carcinoma, the FDA cleared a protocol amendment that removes a previously planned interim analysis and modifies the final analysis to require fewer events, potentially accelerating the path to a readout.

Market context and competitive backdrop

NBTXR3 occupies a distinctive niche within the radiation-oncology space: rather than competing directly with immunotherapy or targeted agents, it is designed to enhance the physical and biological effect of radiotherapy at the tumour site. That mechanism has drawn comparisons with radiosensitisers, but the nanoparticle delivery and proposed immunogenic activation distinguish it from conventional small-molecule approaches. The collaboration with Johnson and Johnson, formalised in 2023, substantially de-risks the late-stage development cost for Nanobiotix while preserving upstream milestones and royalty entitlements.

The NSCLC treatment landscape is intensely competitive, with established checkpoint inhibitors and emerging antibody-drug conjugates setting a high bar for new entrants. The CONVERGE data, while compelling in the context of complete response rates, reflect a seven-patient cohort and cannot yet be used to draw definitive conclusions. Analysts and clinicians will watch whether the response pattern holds as the study enrols further patients, and whether durvalumab consolidation can sustain those responses at 24-month follow-up. The NANORAY-312 amendment is significant operationally: a faster final analysis could bring Nanobiotix closer to a potential first approval in head and neck cancer before the end of the decade.

Nanobiotix also disclosed preclinical data on its Nanoprimer platform at AACR 2026, where pre-treatment with Nanoprimer before lipid nanoparticle-delivered recombinant DNA showed improved systemic bioavailability and reduced hepatic toxicity, pointing to early-stage pipeline optionality beyond NBTXR3.